Viral oncology: molecular biology and pathogenesis

UN Mui, CT Haley, SK Tyring - Journal of clinical medicine, 2017 - mdpi.com
Oncoviruses are implicated in approximately 12% of all human cancers. A large number of
the world's population harbors at least one of these oncoviruses, but only a small proportion …

The role of miRNAs in virus-mediated oncogenesis

Z Vojtechova, R Tachezy - International journal of molecular sciences, 2018 - mdpi.com
To date, viruses are reported to be responsible for more than 15% of all tumors worldwide.
The oncogenesis could be influenced directly by the activity of viral oncoproteins or by the …

Oncogenic viruses and chemoresistance: What do we know?

JS Nahand, N Rabiei, R Fathazam… - Pharmacological …, 2021 - Elsevier
Chemoresistance is often referred to as a major leading reason for cancer therapy failure,
causing cancer relapse and further metastasis. As a result, an urgent need has been raised …

ATAD2 in cancer: a pharmacologically challenging but tractable target

M Hussain, Y Zhou, Y Song, HMA Hameed… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: ATAD2 protein is an emerging oncogene that has strongly been linked to the
etiology of multiple advanced human cancers. Therapeutically, despite the fact that genetic …

[HTML][HTML] HBx promotes hepatocellular carcinoma progression by repressing the transcription level of miR-187-5p

Y Deng, L Wang, Y Zhang, D Sun, H Min… - Aging (Albany …, 2023 - ncbi.nlm.nih.gov
HBV-associated hepatitis B virus x protein (HBx) plays multiple roles in the development of
hepatocellular carcinoma. In our prior study, we discovered that miR-187-5p expression was …

Clinical implication of E2F transcription factor 1 in hepatocellular carcinoma tissues

WY Ye, HP Lu, JD Li, G Chen, RQ He… - Cancer Biotherapy & …, 2023 - liebertpub.com
Background: To date, the clinical management of advanced hepatocellular carcinoma
(HCC) patients remains challenging and the mechanisms of E2F transcription factor 1 …

Molecular initiating events associated with drug-induced liver malignant tumors: an integrated study of the FDA adverse event reporting system and toxicity predictions

K Kurosaki, Y Uesawa - Biomolecules, 2021 - mdpi.com
Liver malignant tumors (LMTs) represent a serious adverse drug event associated with drug-
induced liver injury. Increases in endocrine-disrupting chemicals (EDCs) have attracted …

Insights into the etiology‐associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas

VP Seshachalam, K Sekar… - Journal of gastroenterology …, 2018 - Wiley Online Library
Abstract Background and Aim Hepatitis B virus (HBV), hepatitis C virus, alcohol
consumption, and non‐alcoholic fatty liver disease are the major known risk factors for …

Development of in silico prediction models for drug-induced liver malignant tumors based on the activity of molecular initiating events: Biologically interpretable …

K Kurosaki, Y Uesawa - The Journal of Toxicological Sciences, 2022 - jstage.jst.go.jp
Liver malignant tumors (LMTs) have recently been reported as severe and life-threatening
adverse drug events associated with drug-induced liver injury (DILI). DILIs are the most …

Method of treating with a peptide

M Andrea, T Weinschenk, O Schoor, J Fritsche… - US Patent …, 2020 - Google Patents
2019-11-06 Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …